Your browser is no longer supported. Please, upgrade your browser.
CRSP [NASD]
CRISPR Therapeutics AG
Index- P/E14.23 EPS (ttm)4.76 Insider Own0.50% Shs Outstand76.29M Perf Week0.16%
Market Cap5.08B Forward P/E- EPS next Y-7.04 Insider Trans-14.78% Shs Float72.25M Perf Month-14.07%
Income411.90M PEG- EPS next Q-1.77 Inst Own54.40% Short Float11.14% Perf Quarter-30.13%
Sales902.40M P/S5.63 EPS this Y-550.50% Inst Trans0.19% Short Ratio5.17 Perf Half Y-46.10%
Book/sh32.94 P/B2.06 EPS next Y-244.30% ROA17.30% Target Price149.11 Perf Year-66.09%
Cash/sh33.04 P/C2.05 EPS next 5Y- ROE19.20% 52W Range64.76 - 220.20 Perf YTD-10.57%
Dividend- P/FCF10.93 EPS past 5Y-52.50% ROI-21.30% 52W High-69.22% Beta2.08
Dividend %- Quick Ratio26.20 Sales past 5Y23.80% Gross Margin- 52W Low4.65% ATR4.95
Employees410 Current Ratio26.20 Sales Q/Q700.00% Oper. Margin45.60% RSI (14)39.75 Volatility6.46% 6.62%
OptionableYes Debt/Eq0.00 EPS Q/Q-26.50% Profit Margin45.60% Rel Volume0.97 Prev Close66.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume1.56M Price67.77
Recom2.10 SMA20-9.84% SMA50-14.46% SMA200-38.18% Volume1,507,359 Change2.06%
Dec-07-21Initiated Cowen Market Perform
Oct-19-21Initiated SVB Leerink Outperform $126
Jun-14-21Upgrade Citigroup Sell → Neutral $55 → $132
Apr-21-21Upgrade Jefferies Hold → Buy $172
Mar-04-21Initiated JMP Securities Mkt Outperform $160
Dec-10-20Reiterated Needham Buy $105 → $170
Dec-10-20Reiterated Chardan Capital Markets Buy $110 → $166
Dec-10-20Downgrade Jefferies Buy → Hold
Dec-07-20Downgrade Wells Fargo Overweight → Equal Weight $145
Oct-23-20Initiated RBC Capital Mkts Sector Perform $110
Oct-05-20Initiated BofA Securities Buy $110
Jul-28-20Reiterated Needham Buy $84 → $105
Jul-14-20Initiated SunTrust Buy $140
Jun-15-20Reiterated Canaccord Genuity Buy $80 → $84
Mar-05-20Initiated Stifel Hold $52
Feb-03-20Downgrade Evercore ISI Outperform → In-line $85 → $52
Nov-19-19Upgrade William Blair Mkt Perform → Outperform
Nov-12-19Upgrade Oppenheimer Perform → Outperform $65
Aug-01-19Initiated Jefferies Buy $64
Jul-26-19Initiated Canaccord Genuity Buy $72
Jan-16-22 06:47AM  
06:00AM  
Jan-13-22 03:56PM  
01:38PM  
Jan-11-22 01:52PM  
Jan-10-22 08:17AM  
06:00AM  
Jan-08-22 12:59PM  
Jan-07-22 06:00PM  
Jan-03-22 06:00AM  
Dec-31-21 11:40AM  
Dec-30-21 06:52AM  
05:37AM  
Dec-24-21 05:50PM  
Dec-23-21 06:00PM  
Dec-22-21 04:52PM  
Dec-20-21 05:21PM  
Dec-13-21 08:49AM  
Dec-09-21 01:37PM  
Dec-07-21 02:33PM  
01:09PM  
Dec-05-21 07:30PM  
Dec-03-21 11:31AM  
Nov-25-21 03:34PM  
Nov-23-21 12:01PM  
08:30AM  
Nov-22-21 08:30AM  
Nov-21-21 11:31AM  
Nov-20-21 07:00AM  
Nov-17-21 10:45AM  
Nov-16-21 08:30AM  
Nov-15-21 09:04AM  
Nov-05-21 06:00AM  
Nov-04-21 09:43AM  
07:37AM  
06:31AM  
Nov-03-21 05:15PM  
04:01PM  
10:48AM  
07:00AM  
05:51AM  
Nov-02-21 08:00AM  
Oct-31-21 09:45AM  
Oct-28-21 03:26PM  
Oct-26-21 05:55AM  
Oct-25-21 11:06AM  
Oct-22-21 10:22AM  
07:05AM  
Oct-20-21 03:02PM  
06:10AM  
Oct-19-21 09:25AM  
05:55AM  
Oct-18-21 06:45AM  
Oct-17-21 09:01AM  
Oct-16-21 07:00AM  
06:25AM  
Oct-15-21 10:11AM  
07:47AM  
Oct-14-21 09:40AM  
07:00AM  
Oct-13-21 04:12PM  
10:52AM  
10:08AM  
09:01AM  
08:21AM  
07:54AM  
07:27AM  
06:25AM  
Oct-12-21 04:01PM  
10:50AM  
Oct-08-21 02:35PM  
Oct-07-21 09:10AM  
Oct-05-21 04:05PM  
Oct-01-21 08:00AM  
Sep-30-21 05:50PM  
06:17AM  
05:51AM  
Sep-29-21 06:25AM  
Sep-28-21 08:00AM  
06:45AM  
Sep-23-21 05:55AM  
Sep-22-21 05:50PM  
Sep-17-21 09:30AM  
Sep-16-21 07:22AM  
05:55AM  
Sep-12-21 07:57AM  
Sep-10-21 05:50PM  
Sep-09-21 12:37PM  
07:52AM  
Sep-04-21 07:55AM  
Sep-02-21 05:50PM  
Aug-31-21 09:40AM  
Aug-26-21 12:45PM  
Aug-25-21 09:36AM  
Aug-24-21 09:30AM  
Aug-17-21 10:21AM  
Aug-14-21 08:00AM  
Aug-12-21 05:52AM  
Aug-06-21 02:29PM  
Aug-05-21 08:00AM  
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies; allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. It develops regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, myotonic dystrophy type 1, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. The company was formerly known as Inception Genomics AG and changed its name to CRISPR Therapeutics AG in April 2014. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kulkarni SamarthChief Executive OfficerDec 20Option Exercise1.8117,75032,128279,085Dec 22 08:00 PM
KASINGER JAMES R.General Counsel and SecretaryDec 02Option Exercise13.627,34299,99836,512Dec 03 08:00 PM
Kulkarni SamarthChief Executive OfficerOct 15Option Exercise1.8133,00059,730219,932Oct 18 08:00 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Option Exercise17.7525,000443,75026,891Aug 10 08:00 PM
TOMSICEK MICHAEL JOHNChief Financial OfficerAug 06Sale138.5225,0003,462,9261,891Aug 10 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Option Exercise12.5728,500358,245216,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 05Sale128.9828,5003,675,939187,719Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Option Exercise12.571,50018,855189,219Aug 06 08:00 PM
Kulkarni SamarthChief Executive OfficerAug 04Sale125.021,500187,530187,719Aug 06 08:00 PM
Bolzon Bradley J PhDDirectorJul 19Sale126.4310,0001,264,348148,831Jul 21 05:21 PM
Novak RodgerPresidentJun 30Sale165.0025,0004,125,000573,007Jul 01 05:43 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4810,0001,524,799158,831Jun 30 06:38 PM
Bolzon Bradley J PhDDirectorJun 28Sale152.4820,3753,106,7830Jun 30 06:38 PM
Novak RodgerPresidentJun 21Sale128.6225,0003,215,458623,007Jun 23 05:54 PM
Kulkarni SamarthChief Executive OfficerJun 15Option Exercise12.5730,000377,100217,719Jun 17 05:44 PM
Kulkarni SamarthChief Executive OfficerJun 15Sale126.4330,0003,792,804187,719Jun 17 05:44 PM
Bolzon Bradley J PhDDirectorJun 11Sale126.6110,0001,266,11820,375Jun 15 04:41 PM
Bolzon Bradley J PhDDirectorMar 22Sale132.3730,3744,020,66730,375Mar 24 06:00 PM
Bolzon Bradley J PhDDirectorFeb 19Sale149.11171,00325,497,840168,831Feb 23 04:40 PM
KASINGER JAMES R.General Counsel and SecretaryJan 19Option Exercise51.4927,5001,415,97549,931Jan 20 06:05 PM
KASINGER JAMES R.General Counsel and SecretaryJan 19Sale204.9427,5005,635,94422,431Jan 20 06:05 PM